Pradaxa® MDL Lawsuit Update (MDL 2385): First Pradaxa® Trial Now Set to Begin September 2014

March 13, 2014

Roger C. Denton, Plaintiffs' Co-Lead Counsel in the Pradaxa® MDL, provides an update on the Pradaxa® Multidistrict Litigation (MDL 2385), particularly that the first trial is now set to begin this fall.

St. Louis, MO (PRWEB) March 13, 2014

The first trial in the Pradaxa® Multidistrict Litigation entitled In re: Pradaxa® (Dabigatran Etexilate) Products Liability Litigation (MDL 2385, Case No. 12-md-2385) is set to begin this fall in the United States District Court for the Southern District of Illinois. According to a recent Case Management Order issued by The Honorable Chief Judge David R. Herndon, the first Pradaxa® trial has been set for September 15, 2014.

“The scheduling of the first Pradaxa® trial is of great interest to our firm, as we continue to hear from individuals who allegedly experienced life-threatening episodes of internal bleeding after using Pradaxa®,” says Roger C. Denton, Plaintiffs' Co-Lead Counsel in the Pradaxa® MDL. Schlichter, Bogard & Denton, LLP are leaders in the national Pradaxa® Multidistrict Litigation (MDL 2385). The attorneys at Schlichter, Bogard & Denton, LLP are offering a free and confidential case review to those who allege to have been injured, or lost loved ones, after using Pradaxa®.

Pradaxa® is an oral anticoagulant (blood thinner) launched by Boehringer Ingelheim in October 2010. In December 2011, the U.S. Food and Drug Administration (FDA) issued a Safety Announcement that the FDA was evaluating post-marketing reports of serious – and even fatal – bleeding events in patients taking Pradaxa®. According to the Judicial Panel on Multidistrict Litigation, over 2,000 federal Pradaxa® lawsuits are currently pending against the drug’s manufacturers in the United States District Court for the Southern District of Illinois before the Honorable Chief Judge David R. Herndon, and the number of cases is expected to continue to grow. These individuals allege that they have suffered severe – and often fatal – injuries while using Pradaxa® and that Boehringer Ingelheim failed to adequately warn about bleeding risks and the lack of a reversal agent.

Previously on February 7, 2014, The New York Times reported that numerous documents had been made public in the Pradaxa® Multidistrict Litigation, including emails, memos and internal presentations centered on whether a research paper would undercut Pradaxa®’s main selling points that regular blood tests are not required with use of Pradaxa®. The article noted that the unsealed internal documents demonstrate that Boehringer Ingelheim employees “openly fretted" when it appeared that the results of the research paper, written by Paul A. Reilly, a clinical program director at the company, indicated that some patients could benefit from monitoring of their blood. Further, the article noted that the newly unsealed documents demonstrate that “[t]he makers of the blood-thinning drug Pradaxa® were so worried that [the] internal research paper would damage drug sales that some employees not only pressured the author to revise it, but suggested it should be quashed altogether.”

And before that on December 9, 2013, the federal court presiding over the Pradaxa® Multidistrict Litigation entered an order sanctioning Boehringer Ingelheim, the manufacturer of Pradaxa®, for continued discovery violations. As stated in his 51-page order, Chief Judge David R. Herndon was “stunned” by Boehringer’s “egregious” discovery violations. The Court further found that Boehringer’s actions were in “bad faith,” and that monetary sanctions were warranted in the amount of $931,500. (In re Pradaxa (Dabigatran Extexilate) Products Liability Litigation, MDL No. 2385, Case No. 12-md-2385)

About Schlichter, Bogard & Denton, LLP

Schlichter, Bogard & Denton, LLP is a unique law firm that aggressively represents its clients injured as a result of dangerous pharmaceutical medications and unsafe medical devices, including Pradaxa®. The attorneys at Schlichter, Bogard & Denton, LLP who represent victims harmed by pharmaceutical manufacturers include Roger Denton, Kristine Kraft, Beth Wilkins Flieger, Ashley Brittain Landers, and Tara Rocque. With hard work, creative thinking, and strong trial skills, we have earned an outstanding nationwide reputation by representing thousands of individuals who have suffered serious injuries. If you or a loved one has suffered injuries after using the blood thinning medication Pradaxa®, please contact the attorneys at Schlichter, Bogard & Denton, LLP toll-free at 1-800-873-5297 for your confidential and free consultation.

Schlichter, Bogard & Denton, LLP also welcomes the opportunity to work with other attorneys on these types of cases. Schlichter, Bogard & Denton, LLP is available to either handle these cases or work as co-counsel, so other attorneys with Pradaxa® cases are invited to contact an attorney at the firm to explore this opportunity.

The choice of a lawyer is an important decision and should not be based solely on advertisements. The cases discussed do not predict outcomes in future cases. Past results afford no guarantee of future results and every case is different and must be judged on its own merits.

For the original version on PRWeb visit: http://www.prweb.com/releases/2014/03/prweb11661618.htm

Source: prweb

comments powered by Disqus